Header Logo

Connection

PHILIP NG to Genetic Vectors

Back to Details
This is a "connection" page, showing publications PHILIP NG has written about Genetic Vectors.
PHILIP NG
Connection Strength
4.738
Genetic Vectors
  1. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum Gene Ther. 2013 Aug; 24(8):761-5.
    View in: PubMed
    Score: 0.326
  2. Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques. Mol Ther. 2012 Oct; 20(10):1863-70.
    View in: PubMed
    Score: 0.303
  3. Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors. Hum Gene Ther. 2011 Apr; 22(4):483-8.
    View in: PubMed
    Score: 0.275
  4. Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges. Curr Pharm Des. 2011; 17(24):2488-99.
    View in: PubMed
    Score: 0.272
  5. Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad. Mol Ther. 2010 Jul; 18(7):1339-45.
    View in: PubMed
    Score: 0.260
  6. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr Gene Ther. 2009 Oct; 9(5):329-40.
    View in: PubMed
    Score: 0.250
  7. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther. 2009 May; 20(5):479-85.
    View in: PubMed
    Score: 0.242
  8. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther. 2009 Feb; 17(2):327-33.
    View in: PubMed
    Score: 0.236
  9. Methods for the production of helper-dependent adenoviral vectors. Methods Mol Biol. 2008; 433:33-53.
    View in: PubMed
    Score: 0.221
  10. Methods for the production of first generation adenoviral vectors. Methods Mol Biol. 2008; 433:55-78.
    View in: PubMed
    Score: 0.221
  11. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther. 2007 Apr; 15(4):732-40.
    View in: PubMed
    Score: 0.208
  12. Progress towards the clinical application of helper-dependent adenoviral vectors for liver and lung gene therapy. Curr Opin Mol Ther. 2006 Oct; 8(5):446-54.
    View in: PubMed
    Score: 0.203
  13. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther. 2006 Apr; 17(4):391-404.
    View in: PubMed
    Score: 0.196
  14. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther. 2005 Jul; 12(1):99-106.
    View in: PubMed
    Score: 0.186
  15. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther. 2005 Jul; 16(7):811-20.
    View in: PubMed
    Score: 0.186
  16. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther. 2005 Jan; 16(1):1-16.
    View in: PubMed
    Score: 0.180
  17. Physical and infectious titers of helper-dependent adenoviral vectors: a method of direct comparison to the adenovirus reference material. Mol Ther. 2004 Oct; 10(4):792-8.
    View in: PubMed
    Score: 0.176
  18. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther. 2004 Jan; 15(1):35-46.
    View in: PubMed
    Score: 0.168
  19. Improved system for helper-dependent adenoviral vector production. Mol Ther. 2003 Nov; 8(5):846-52.
    View in: PubMed
    Score: 0.166
  20. Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol. 2002 May; 76(9):4181-9.
    View in: PubMed
    Score: 0.149
  21. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther. 2013 Apr; 21(4):796-805.
    View in: PubMed
    Score: 0.078
  22. Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum Gene Ther. 2012 Oct; 23(10):1065-70.
    View in: PubMed
    Score: 0.076
  23. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A. 2005 Mar 15; 102(11):3930-5.
    View in: PubMed
    Score: 0.045
  24. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005 Jan; 11(1):66-79.
    View in: PubMed
    Score: 0.045
  25. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol Genet Metab. 2005 Mar; 84(3):278-88.
    View in: PubMed
    Score: 0.045
  26. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb; 15(2):386-92.
    View in: PubMed
    Score: 0.013
  27. Modulation of adenoviral transduction in vitro and in vivo by hyaluronan and its receptor CD44. Mol Ther. 2007 Mar; 15(3):566-70.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.